Cytokinetics Inc. (CYTK) Initiates Enrollment for Phase II Clinical Trial of Lead Drug Candidate
Cytokinetics Inc., a clinical-stage biopharmaceutical company, today announced it has initiated enrollment for a second phase II clinical trial of CK-2017357, the company’s lead drug candidate stemming from the company’s skeletal muscle contractility program. CK-2017357 has been granted orphan-drug status by the United States Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis (ALS). The company anticipates enrolling about 24 patients to conduct the study at eight to ten study centers. The clinical trial is a double-blind, randomized, placebo-controlled trial focused on evaluating the safety and tolerability of CK-2017357 in patients with ALS. “We are pleased to…